Therapy Areas: AIDS & HIV
Johnson & Johnson to invest more than USD500m in next four years
8 October 2019 -

United States-based Johnson & Johnson is planning to invest more than USD500m in the next four years to help end the epidemics of HIV and tuberculosis, it was reported yesterday.

The company is to utilise the investment to advance research and development and delivery programmes with the intention of eliminating both diseases by 2030.

The company has chosen a team of researchers that will use its scientific resources, to improve the discovery, development and delivery of next generation medicines and vaccines. When combined with other global programmes, the investment initiative is also intended to help achieve the United Nations Sustainable Development Goal 3 targets. The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) is to continue to advance an investigational mosaic-based vaccine regimen to prevent HIV along with a consortium of partners, as part of the USD500m investment.

The firm has completed hiring 2,600 women in an ongoing Imbokodo efficacy trial in Southern Africa and is also set to begin the second efficacy trial in North America, South America and Europe.